: iStockAnalyst.com Symbols Feed

Notable Bankruptcies of 2008: Final Tally

Mon, 05 Jan 2009 23:35:00 GMT

In mid-August I predicted that “major” bankruptcies for 2008 would reach 225 (see Bankruptcies Revisited). Through October there had been 172 such bankruptcies, as reported by Bankrupctydata.com. That implied a pace of around 210 bankruptcies, well short of my prediction. At the time however, I suggested that the filing pace was likely to quicken in November and December as the economy deteriorated at a more rapid clip. Sure enough, the final numbers bear out my prediction. According to Bankruptcydata.com, “major” filings reached 231 in 2008. 231 bankruptcies falls far short of the 289 “major” bankruptcies in 2000 and 383 in 2001[More...]

Bankruptcies Revisited

Thu, 06 Nov 2008 04:34:00 GMT

In mid-August I predicted that bankruptcies for 2008 would reach 225 (see my post Bankruptcy Update). There had been 120 total bankruptcies at the time. The 120 bankruptcies as of August 15th implied a pace of about 195 bankruptcies, well shy of my prediction. But much has changed since mid-August, so let’s revisit that prediction. According to Bankrupctydata.com, there have been 172 bankruptcies through October. If we assume that bankruptcies continue to accumulate at 17 per month for the rest of the year (the monthly average), the implied total for 2008 would be 206. However, we know that the bankruptcy pace has quickened since August. In fact, since mid-August, bankruptcies have been averaging about 21 per month. If we use 21 per month instead[More...]

Dummy Trade of the Day - VMware, Inc. (Public, NYSE:VMW)

Tue, 02 Oct 2007 01:53:07 GMT

VMW -Mentioned by Alex in the comments this weekend - 3 inside bars on declining volume. Partial booked as price approached R2 and closed balance after price couldn't hold $89.00.[More...]

AdvanSource Biomaterials Files Patent for Silicone-Urethane Copolymers

Thu, 05 Nov 2009 18:50:00 GMT

AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced the recent filing of a patent for its newly launched ChronoSil polymer product, a silicone-urethane copolymer.
ChronoSil can have many physical properties which are usually associated with polyurethanes, but also the feel and characteristics of silicones.
The ChronoSil product family maintains the inherent benefits of a polycarbonate-based urethane, including high pressure resistance, tensile-strength and superior chemical resistance combined with silicone's industry-recognized advantages such as heightened elongation, superior elasticity and a low coefficient of friction.

[More...]

AdvanSource Biomaterials Announces Fiscal 2010 First Quarter Conference Call for August 13, 2009

Fri, 31 Jul 2009 21:48:00 GMT

AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced the Company will host a conference call for investors on Thursday, August 13, 2009 at 2:30 PM Eastern to discuss its fiscal first quarter results as well as recent developments.
The call can be accessed by interested parties by dialing: 800-510-0219 within the U.S. or 617-614-3451 outside the U.S. and entering the passcode: 35947047.
A replay of the conference call will be available two hours after the call for the following two business days by dialing: 888-286-8010 within the U.S. or 617-801-6888 outside the U.S. and entering passcode: 95137042.

[More...]

AdvanSource Biomaterials Announces Change in Auditors

Wed, 01 Apr 2009 17:58:00 GMT

AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has selected Vitale, Caturano & Company P.C. to serve as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2009. Vitale, Caturano replaces the Company’s previous independent registered public accountants, Ernst & Young LLP.[More...]

AdvanSource Biomaterials Announces Changes in Senior Financial Management

Wed, 04 Mar 2009 20:01:00 GMT

AdvanSource Biomaterials Corporation (NYSE Alternext US: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced that Eric Walters, the Company’s CFO, has offered his resignation to pursue other personal interests, which the Company has accepted. The Company also announced the appointment of David Volpe as interim CFO.[More...]

AdvanSource Biomaterials Reports Third Quarter Financial Results

Wed, 18 Feb 2009 12:28:00 GMT

AdvanSource Biomaterials Corporation (NYSE Alternext US: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today reported financial results for the fiscal third quarter and nine months ended December 31, 2008. The Company’s financial condition and results of operations, which are based on the Company’s continuing operations, exclude the financial condition and results of operations of Gish BioMedical, Inc. and Catheter and Disposables Technology, Inc. (“CDT”) in prior year periods, both formerly wholly-owned subsidiaries of the Company, which were sold during the fiscal year ended March 31, 2008.[More...]

AdvanSource Announces Conference Call on February 18 at 2:30 PM Eastern For Third Quarter of Fiscal 2009

Mon, 09 Feb 2009 15:00:00 GMT

AdvanSource Biomaterials Corporation (NYSE Alternext US: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, announced today that it will release its results for the third quarter of fiscal 2009 before the market opens on Wednesday, February 18, 2009. Following the release, the Company will host a conference call for investors at 2:30 p.m. ET (11:30 a.m. PT) to discuss its fiscal third quarter results as well as recent developments. The February 18 date is later than usual due to travel commitments for a major industry conference and expo in California during the prior week.[More...]

AdvanSource Biomaterials to Showcase its Innovative Technology at MD&M West Expo on February 10-12

Wed, 04 Feb 2009 14:17:00 GMT

AdvanSource Biomaterials Corporation (NYSE Alternext US: ASB), a leading developer of advanced polymer materials for a broad range of medical devices announced today that it will be showcasing its innovative technology at the world's largest medical OEM event -- Medical Design & Manufacturing (MD&M West) -- that will take place February 10-12 at the Anaheim Convention Center in California.[More...]

AdvanSource Biomaterials’ Antimicrobials Patent Application Published by U.S. Patent Office

Tue, 06 Jan 2009 17:56:00 GMT

AdvanSource Biomaterials Corporation (NYSE Alternext US: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, announced today notification of the publication by the U.S. Patent and Trademark Office of the Company’s U.S. patent application related to antimicrobial polyurethane polymers.[More...]

AdvanSource Biomaterials Receives Key ISO Certifications for Design & Manufacture of Polymers for the Medical Device Industry

Wed, 03 Dec 2008 18:26:00 GMT

AdvanSource Biomaterials Corporation (NYSE Alternext US: ASB), a leading developer of advanced polymer materials for a broad range of medical device applications, today announced that after assessment by the International Organization for Standardization (ISO), the Company’s Quality Management System has received ISO certification through SGS United Kingdom Ltd. to ISO13485:2003 and 9001:2000 for the design and manufacture of polymers for the medical device industry. ISO certification is the preeminent worldwide standard for manufacturing and quality control systems.[More...]

Company Profile for AdvanSource Biomaterials Corporation

Fri, 14 Nov 2008 14:36:00 GMT

AdvanSource Biomaterials Corporation manufactures advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company’s biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. AdvanSource’s business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. The Company is conducting a clinical trial for regulatory approval at two sites in Europe for its CardioPass™ synthetic coronary bypass graft. More information about AdvanSource is available at its website: www.advbiomaterials.com.[More...]

Form 4 AdvanSource Biomaterials For: May 08 Filed by: ARMINI ANTHONY J (10K)

Wed, 03 Jun 2009 19:42:00 GMT

[More...]

Form 4 ADAMS MICHAEL F For: May 08 (10K)

Tue, 12 May 2009 23:03:00 GMT

[More...]

Form 4 AdvanSource Biomaterials For: May 08 Filed by: ONEILL WILLIAM J JR (10K)

Tue, 12 May 2009 22:52:00 GMT

[More...]

Form 4 BARRETTI MICHAEL L For: May 08 (10K)

Tue, 12 May 2009 22:41:00 GMT

[More...]

Form 4 ADAMS MICHAEL F For: May 12 (10K)

Tue, 12 May 2009 22:17:00 GMT

[More...]